B. Riley Wealth Management’s Dianthus Therapeutics DNTH Stock Holding History

B. Riley Wealth Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$13	Buy	+669	New	+$16.5K	﹤0.01%	748

Other funds holding DNTH

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

B. Riley Wealth Management's DNTH Position: Q2 2022 in Review

B. Riley Wealth Management opened a new position in Dianthus Therapeutics (DNTH) in Q2 2022: 669 shares worth $13. The stake represents ﹤0.01% of the portfolio and ranks #748 among its holdings.

75 funds tracked by Wall St. Rank hold DNTH as of Q2 2022.

B. Riley Wealth Management held 669 shares of Dianthus Therapeutics worth $13 as of Q2 2022.
Dianthus Therapeutics was a new B. Riley Wealth Management position in Q2 2022.
Dianthus Therapeutics made up ﹤0.01% of B. Riley Wealth Management's portfolio in Q2 2022, its #748 holding.
75 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2022.

Based on B. Riley Wealth Management's 13F filing for Q2 2022, filed 9 Sep 2022.